Glaxosmithkline Plc Adr Stock Performance
| GSK Stock | USD 34.33 0.31 0.91% |
The company retains a Market Volatility (i.e., Beta) of 0.28, which attests to not very significant fluctuations relative to the market. As returns on the market increase, GlaxoSmithKline PLC's returns are expected to increase less than the market. However, during the bear market, the loss of holding GlaxoSmithKline PLC is expected to be smaller as well. At this point, GlaxoSmithKline PLC ADR has a negative expected return of -0.36%. Please make sure to check out GlaxoSmithKline PLC's potential upside, and the relationship between the jensen alpha and rate of daily change , to decide if GlaxoSmithKline PLC ADR performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days GlaxoSmithKline PLC ADR has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's basic indicators remain quite persistent which may send shares a bit higher in December 2024. The latest mess may also be a sign of long-standing up-swing for the company institutional investors. ...more
Actual Historical Performance (%)
One Day Return 0.91 | Five Day Return 1.48 | Year To Date Return (8.48) | Ten Year Return (26.09) | All Time Return 5.1 K |
Forward Dividend Yield 0.0456 | Payout Ratio 0.3707 | Last Split Factor 1226:1000 | Forward Dividend Rate 1.56 | Dividend Date 2025-01-09 |
| GlaxoSmithKline PLC dividend paid on 10th of October 2024 | 10/10/2024 |
1 | GSK plc Q3 2024 Earnings Call Transcript | 10/31/2024 |
2 | GSK Cut to Hold at Deutsche Bank Aktiengesellschaft | 11/15/2024 |
3 | GSKs phase III trial of linerixibat shows promise for PBC itch | 11/19/2024 |
4 | Mutated Bird Flu Case In California Puts Humans At Increased Risk, So Which Companies Are Developing Vaccines | 11/20/2024 |
5 | Connor Clark Lunn Investment Management Ltd. Acquires 456,319 Shares of GSK plc | 11/21/2024 |
6 | Premature Ejaculation Treatment Market to Grow by USD 1.46 Billion , Boosted by Effective Off-Label Drugs, Market Evolution Powered by AI - Technavio | 11/22/2024 |
7 | V.MDCX Medicus Pharma Has Begun Trading on Nasdaq under the ticker MDCX after Completing an IPO in the U.S. The SKNJCT-003 Phase 2 clinical trial continues. | 11/25/2024 |
8 | ALEC Stock Tanks as Alzheimers Drug Fails in Mid-Stage Study | 11/27/2024 |
| Begin Period Cash Flow | 3.4 B | |
| Total Cashflows From Investing Activities | -1.6 B |
GlaxoSmithKline |
GlaxoSmithKline PLC Relative Risk vs. Return Landscape
If you would invest 4,341 in GlaxoSmithKline PLC ADR on August 30, 2024 and sell it today you would lose (908.00) from holding GlaxoSmithKline PLC ADR or give up 20.92% of portfolio value over 90 days. GlaxoSmithKline PLC ADR is generating negative expected returns assuming volatility of 1.4699% on return distribution over 90 days investment horizon. In other words, 13% of stocks are less volatile than GlaxoSmithKline, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
GlaxoSmithKline PLC Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for GlaxoSmithKline PLC's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as GlaxoSmithKline PLC ADR, and traders can use it to determine the average amount a GlaxoSmithKline PLC's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2457
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | GSK |
Estimated Market Risk
| 1.47 actual daily | 13 87% of assets are more volatile |
Expected Return
| -0.36 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.25 actual daily | 0 Most of other assets perform better |
Based on monthly moving average GlaxoSmithKline PLC is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of GlaxoSmithKline PLC by adding GlaxoSmithKline PLC to a well-diversified portfolio.
GlaxoSmithKline PLC Fundamentals Growth
GlaxoSmithKline Stock prices reflect investors' perceptions of the future prospects and financial health of GlaxoSmithKline PLC, and GlaxoSmithKline PLC fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on GlaxoSmithKline Stock performance.
| Return On Equity | 0.22 | ||||
| Return On Asset | 0.0724 | ||||
| Profit Margin | 0.08 % | ||||
| Operating Margin | 0.08 % | ||||
| Current Valuation | 85.1 B | ||||
| Shares Outstanding | 2.04 B | ||||
| Price To Earning | 11.80 X | ||||
| Price To Book | 3.98 X | ||||
| Price To Sales | 2.24 X | ||||
| Revenue | 30.33 B | ||||
| Gross Profit | 19.92 B | ||||
| EBITDA | 9.08 B | ||||
| Net Income | 5.31 B | ||||
| Cash And Equivalents | 3.72 B | ||||
| Cash Per Share | 0.32 X | ||||
| Total Debt | 18.02 B | ||||
| Debt To Equity | 0.98 % | ||||
| Current Ratio | 1.43 X | ||||
| Book Value Per Share | 3.43 X | ||||
| Cash Flow From Operations | 6.77 B | ||||
| Earnings Per Share | 1.53 X | ||||
| Market Capitalization | 70.04 B | ||||
| Total Asset | 59.01 B | ||||
| Retained Earnings | 7.74 B | ||||
| Working Capital | (2.42 B) | ||||
| Current Asset | 16.59 B | ||||
| Current Liabilities | 13.42 B | ||||
About GlaxoSmithKline PLC Performance
By examining GlaxoSmithKline PLC's fundamental ratios, stakeholders can obtain critical insights into GlaxoSmithKline PLC's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that GlaxoSmithKline PLC is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 234.30 | 216.13 | |
| Return On Tangible Assets | 0.13 | 0.19 | |
| Return On Capital Employed | 0.18 | 0.17 | |
| Return On Assets | 0.08 | 0.15 | |
| Return On Equity | 0.37 | 0.47 |
Things to note about GlaxoSmithKline PLC ADR performance evaluation
Checking the ongoing alerts about GlaxoSmithKline PLC for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for GlaxoSmithKline PLC ADR help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| GlaxoSmithKline PLC generated a negative expected return over the last 90 days | |
| On 10th of October 2024 GlaxoSmithKline PLC paid $ 0.3857 per share dividend to its current shareholders | |
| Latest headline from zacks.com: ALEC Stock Tanks as Alzheimers Drug Fails in Mid-Stage Study |
- Analyzing GlaxoSmithKline PLC's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether GlaxoSmithKline PLC's stock is overvalued or undervalued compared to its peers.
- Examining GlaxoSmithKline PLC's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating GlaxoSmithKline PLC's management team can have a significant impact on its success or failure. Reviewing the track record and experience of GlaxoSmithKline PLC's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of GlaxoSmithKline PLC's stock. These opinions can provide insight into GlaxoSmithKline PLC's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.28) | Dividend Share 0.61 | Earnings Share 1.53 | Revenue Per Share 15.38 | Quarterly Revenue Growth (0.02) |
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.